AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9408426
Drug: Heparin-coated 7-FR
RxNorm normalized name: Heparine
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heparin-coated 7-FR femoral venous catheters
Trial: 8208641
Drug: Lisinopril 10‐40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 10‐40 mg once daily
Trial: 8208641
Drug: Nifedipine 20‐40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 20‐40 mg twice daily
Trial: 3114434
Drug: CP (cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP (cyclophosphamide and cisplatin both administered intravenously on a single day at 3‐week intervals)
Trial: 24934484
Drug: Cilostazol (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilostazol (up to 200 mg/day)
Trial: 19105351
Drug: Chinese herbal
RxNorm normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbal medicine treatment for flat warts, 5 g pre-pack, treated for 30 days.
Trial: 19105351
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine treatment for flat warts (control group).
Trial: 16632814
Drug: tropisetron (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tropisetron (0.1 mg/kg)
Trial: 2205961
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg zinc sulphate as a depot tablet = 22 mg Zn++ (Zinclet), taken thrice daily for eight weeks
Trial: 2205961
Drug: Placebo, taken
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, taken thrice daily for eight weeks
Trial: 2205961
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg zinc sulphate as a depot tablet = 22 mg Zn++ (Zinclet)
Trial: 626821
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of hepatic artery ligation and portal vein perfusion
Trial: 31399448
Drug: Glutathione (GSH)
DrugBank: Glutathione (DB00143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutathione (GSH) infusion (2500 mg/25 mL over 10 min, followed by the same doses at 24, 48, and 72 hours)
Trial: 25348807
Drug: Subcutaneous infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous infiltration of both wound edges with 20 ml of 0.75% ropivacaine
Trial: 23480028
Drug: Fentanyl (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (5 μg/kg) intravenously alone
Trial: 23480028
Drug: Fentanyl (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (5 μg/kg) intravenously with rifampicin (600 mg single oral dose)
Trial: 22153009
Drug: tirofiban +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tirofiban + aspirin and clopidogrel
Trial: 19786678
Drug: Dihydropyridine calcium
RxNorm normalized name: 4-(2'-Nitrophenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarbonsäuredimethylester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydropyridine calcium channel blocker (CCB)
Trial: 19786678
Drug: GFR between
RxNorm normalized name: CYCLIZED P12 (PEPTIDE BOND BETWEEN THE CARBOXY AND AMINO-TERMINAL ENDS OF THE LINEAR PEPTIDE PSHISKYILRWRPK)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GFR between 31 and 40 mL/min/1.73 m²
Trial: 19786678
Drug: GFR <
RxNorm normalized name: Glomerular Filtration Rate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GFR < 30 mL/min/1.73 m²
Trial: 19786678
Drug: GFR 41
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GFR 41 to 50 mL/min/1.73 m²
Trial: 16941613
Drug: Cromolyn sodium
RxNorm normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cromolyn sodium nasal spray
Trial: 16941613
Drug: Cromolyn sodium
RxNorm normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cromolyn sodium nasal spray and hydroxyurea capsule
Trial: 16941613
Drug: Hydroxyurea capsule
RxNorm normalized name: Hydroxyurea Capsules
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea capsule and placebo nasal spray
Trial: 7709462
Drug: Lisinopril (LIS,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (LIS, 10‐20 mg o.d.)
Trial: 7709462
Drug: Nitrendipine (NIT,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine (NIT, 10‐20 mg b.i.d.)
Trial: 30056216
Drug: acebilustat 50
RxNorm normalized name: Acebilustat
DrugBank: Acebilustat (DB15385)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acebilustat 50 mg
Trial: 30056216
Drug: acebilustat 100
RxNorm normalized name: Acebilustat
DrugBank: Acebilustat (DB15385)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acebilustat 100 mg
Trial: 27362705
Drug: Traditional oral
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional oral medication (Group-I, control)
Trial: 20966373
Drug: Culturally sensitive
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culturally sensitive collaborative treatment (CSCT)
Trial: 19132271
Drug: Predictive equation
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Predictive equation I: W(kg) = 0.5030 (AC) + 0.5634 (AbC) + 1.3180 (CC) + 0.0339 (SSSF) - 43.1560
Trial: 19132271
Drug: Predictive equation
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Predictive equation II: W(kg) = 0.4808 (AC) + 0.5646 (AbC) + 1.3160 (CC) - 42.2450
Trial: 19132271
Drug: Predictive equation
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Predictive equation III: W(kg) = 0.5759 (AC) + 0.5263 (AbC) + 1.2452 (CC) - 4.8689 (S) - 32.9241
Trial: 15845683
Drug: Fluvoxamine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (100 mg daily)
Trial: 15845683
Drug: Fluvoxamine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (100 mg daily) and Erythromycin (1500 mg)
Trial: 12960646
Drug: Inactivated HAV
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated HAV vaccine (Havrix), 720 Elisa units per 0.5 ml dose, administered at months 0 and 6
Trial: 6970272
Drug: Rifampin prophylaxis
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin prophylaxis (20 mg/kg once daily for four days)
Trial: 22010250
Drug: PHL-NP122 (10^6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHL-NP122 (10^6 spores/g of feed)
Trial: 22010250
Drug: PHL-MM65 (10^6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHL-MM65 (10^6 spores/g of feed)
Trial: 19321970
Drug: Comparator (antidepressant)
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator (antidepressant)
Trial: 17446205
Drug: alpha-lactalbumin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha-lactalbumin (40 g)
Trial: 27435836
Drug: Dexmedetomidine (Dex)
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine (Dex) intravenous infusion (0.24 to 0.6 μg/kg/h) for <24 hours postoperatively
Trial: 22446609
Drug: Four cycles
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four cycles of ABVD followed by 30 Gy of involved-field radiation therapy
Trial: 22446609
Drug: Two cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two cycles of ABVD followed by 20 Gy of involved-field radiation therapy
Trial: 22446609
Drug: 30 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 Gy of involved-field radiation therapy
Trial: 22446609
Drug: 20 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 Gy of involved-field radiation therapy
Trial: 19552060
Drug: Antihypertensive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive therapy for 3 months
Trial: 19552060
Drug: Control subjects
RxNorm normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control subjects (no antihypertensive therapy)
Trial: 12883138
Drug: Serotonin reuptake
RxNorm normalized name: Selective serotonin reuptake inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serotonin reuptake inhibitors (SRIs) including clomipramine, fluvoxamine, fluoxetine, sertraline, and paroxetine
Trial: 12883138
Drug: Switching, augmentation,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switching, augmentation, or novel-agent strategies for patients who do not respond to SRIs
Trial: 11021272
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment consisting of ACE inhibitors (91% of patients), ACE inhibitor dosage (52% of recommended dose), β‐blockers (42%), diuretics (70%), digitalis (63%)
Trial: 2336056
Drug: Solution A
RxNorm normalized name: I.V. SOLUTION ADDITIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution A (sucrose and maltodextrin)
Trial: 2336056
Drug: Solution B
RxNorm normalized name: DONISLECEL-JUJN RINSE SOLUTION BAG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution B (glucose)
Trial: 6986133
Drug: Diazepam (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (15 to 25 mg/day)
Trial: 22924169
Drug: Dexamethasone 0.30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 0.30 mg/kg
Trial: 16244842
Drug: 0.8% isoflurane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8% isoflurane with 2 mg/kg succinylcholine
Trial: 16244842
Drug: 1.4% isoflurane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.4% isoflurane with 2 mg/kg succinylcholine
Trial: 9472058
Drug: Iodixanol 270
RxNorm normalized name: IODIXANOL 270mgI/ml INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodixanol 270 mgI/ml
Trial: 9472058
Drug: Iohexol 300
RxNorm normalized name: IOHEXOL 300MG/ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iohexol 300 mgI/ml
Trial: 2468975
Drug: Diltiazem (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (90 mg every 6 h for up to 14 days)
Trial: 1123173
Drug: Metiamide (histamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metiamide (histamine H2-receptor antagonist)
Trial: 935972
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Metiamide and Propantheline
Trial: 6987023
Drug: Hydrochlorothiazide 100
RxNorm normalized name: hydrochlorothiazide 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 100 mg
Trial: 29339109
Drug: Bitter gourd
RxNorm normalized name: BITTER MELON
DrugBank: Momordica charantia fruit (DB14265)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bitter gourd (2.5g powder daily)
Trial: 26651352
Drug: Cognitive-behavioral conjoint
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral conjoint therapy for PTSD (CBCT for PTSD)
Trial: 24684245
Drug: Thyroid hormone
RxNorm normalized name: Thyroid hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroid hormone (thyroxine, T4) supplementation at doses of 4, 8, and 16 μg/(kg · day), bolus or continuous administration
Trial: 15848674
Drug: tacrolimus+steroids+MMF (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tacrolimus+steroids+MMF (control arm)
Trial: 1978468
Drug: Remoxipride (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remoxipride (mean daily dose: 363 mg)
Trial: 1978468
Drug: Haloperidol (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (mean daily dose: 9 mg)
Trial: 18253955
Drug: Activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal (AC) at a dose of 250 mg three times daily during irinotecan administration
Trial: 12839320
Drug: Child Health
RxNorm normalized name: Senna-Relief Childs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Child Health Questionnaire (CHQ‐PF28) administered at 14 days after ED visit
Trial: 10919300
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg morphine intraarticularly
Trial: 10919300
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg morphine intraarticularly
Trial: 10919300
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg saline intraarticularly and morphine intravenously
Trial: 1488460
Drug: Behavioral family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral family treatment
Trial: 1488460
Drug: Supportive family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive family treatment
Trial: 2951818
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide + fenoterol (1 puff per 10 kg body weight, max 4 puffs; each puff contains 0.02 mg ipratropium bromide and 0.05 mg fenoterol)
Trial: 27753676
Drug: Z-track technique
RxNorm normalized name: Z-160
DrugBank: Z-160 (DB12743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Z-track technique for intramuscular injection
Trial: 27753676
Drug: Standard technique
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard technique of intramuscular injection
Trial: 25002101
Drug: Jian-Wei-Qu-Tong Pills
RxNorm normalized name: beef tongue preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jian-Wei-Qu-Tong Pills (JWQTP) high-dose group
Trial: 25002101
Drug: Jian-Wei-Qu-Tong Pills
RxNorm normalized name: beef tongue preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jian-Wei-Qu-Tong Pills (JWQTP) low-dose group
Trial: 15902961
Drug: Humanized anti-IL-6R
RxNorm normalized name: humanized SMART Anti-IL-12 Antibody
DrugBank: humanized SMART Anti-IL-12 Antibody (DB05848)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Humanized anti-IL-6R monoclonal antibody (MRA), administered every 2 weeks for 12 weeks
Trial: 15902961
Drug: Single MRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single MRA infusion
Trial: 31039172
Drug: Aerosol-intradermal vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosol-intradermal vaccination (Group 1)
Trial: 31039172
Drug: Intradermal-aerosol vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal-aerosol vaccination (Group 2)
Trial: 31039172
Drug: Intradermal-intradermal vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal-intradermal vaccination (Group 3)
Trial: 17066402
Drug: Bayesian evaluation
RxNorm normalized name: Babesia microti preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bayesian evaluation of group sequential clinical trial designs
Trial: 8550254
Drug: 100 g
RxNorm normalized name: Berri-Freez 4.5 GM per 100 GM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 g of artificially 13C‐labelled glucose dissolved in 400 ml of water
Trial: 19793150
Drug: Barrier-strengthening moisturizing
RxNorm normalized name: Soothe & Cool Moisture Barrier
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Barrier-strengthening moisturizing cream as maintenance therapy
Trial: 19793150
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment after initial steroid course
Trial: 16145305
Drug: Medroxyprogesterone acetate,
RxNorm normalized name: medroxyprogesterone acetate, micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate, 10 mg/day
Trial: 16145305
Drug: Nomegestrol acetate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nomegestrol acetate, 5 mg/day
Trial: 16145305
Drug: Dydrogesterone, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dydrogesterone, 10 mg/day
Trial: 16145305
Drug: Micronized progesterone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized progesterone, 200 mg/day
Trial: 9486936
Drug: Lisinopril alone
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lisinopril alone (monotherapy)
Trial: 9486936
Drug: Lisinopril with
RxNorm normalized name: LISINOPRIL 20 mg / HYDROCHLOROTHIAZIDE 25 mg ORAL TABLET [Lisinopril with Hydrochlorothiazide]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril with trichlormethiazide (combination therapy)
Trial: 3315173
Drug: Pseudomonas vaccine
RxNorm normalized name: Pseudomonas aeruginosa
DrugBank: Pseudomonas aeruginosa (DB19284)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pseudomonas vaccine immunotherapy
Trial: 3315173
Drug: Tamoxifen with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen with FAC chemotherapy
Trial: 14698135
Drug: FAC chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FAC chemotherapy
Trial: 26481811
Drug: Selenium supplementation
RxNorm normalized name: Selenium supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium supplementation (60 μg/d)
Trial: 25395311
Drug: IBUNa 2
RxNorm normalized name: OCTINOXATE 2010 mg in 30 mL / OCTOCRYLENE 900 mg in 30 mL / TITANIUM DIOXIDE 600 mg in 30 mL TOPICAL EMULSION [SHISEIDO SYNCHRO SKIN SELF-REFRESHING TINT 215 Light Buna]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBUNa 2 × 256 mg
Trial: 22526014
Drug: Moxifloxacin 400
RxNorm normalized name: moxifloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 400 mg administered intravenously prior to surgery
Trial: 19017409
Drug: Norepinephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine infusion (n = 16)
Trial: 19017409
Drug: Phenylephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine infusion (n = 16)
Trial: 16895622
Drug: Doxapram 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxapram 1 mg kg(‐1)
Trial: 16895622
Drug: Aminophylline 2
RxNorm normalized name: aminophylline 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline 2 mg kg(‐1)
Trial: 16895622
Drug: Saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline placebo intravenous
Trial: 1607083
Drug: Supplemental oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental oxygen via oral route (2 liters/min)
Trial: 7964858
Drug: IVIg treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIg treatment
Trial: 30307129
Drug: 4-mm implants
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-mm implants
Trial: 30307129
Drug: 10 or
RxNorm normalized name: K-10 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 or 8-mm long implants
Trial: 30307129
Drug: Long implants
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long implants in augmented bone
Trial: 26721935
Drug: Eldelumab 25
RxNorm normalized name: Eldelumab
DrugBank: Eldelumab (DB06116)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eldelumab 25 mg/kg
Trial: 26721935
Drug: Eldelumab 15
RxNorm normalized name: Eldelumab
DrugBank: Eldelumab (DB06116)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eldelumab 15 mg/kg
Trial: 22060048
Drug: Maxillary sinus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maxillary sinus floor augmentation surgery
Trial: 20594588
Drug: Secondary measures
RxNorm normalized name: MEASLES VIRUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secondary measures favoring intensive therapy
Trial: 18854722
Drug: Fluoxetine (20-60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20-60 mg by mouth per day)
Trial: 12242602
Drug: Mirtazapine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine (15 mg for 2 days, then 30 mg for 5 days) plus phenytoin (200 mg daily for 17 days)
Trial: 12242602
Drug: Phenytoin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenytoin (200 mg daily from day 8 to day 17) plus mirtazapine (15 mg for 2 days, then 30 mg for 15 days)
Trial: 12242602
Drug: Phenytoin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenytoin (200 mg daily)
Trial: 10080828
Drug: rhIFN-gamma injections
RxNorm normalized name: gamma-octalactone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIFN-gamma injections paired with PG
Trial: 10080828
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline injections paired with PG
Trial: 10080828
Drug: rhIFN-gamma injections
RxNorm normalized name: gamma-octalactone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIFN-gamma injections alone
Trial: 7653318
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg nicotine gum (0 pieces per day)
Trial: 7653318
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg nicotine gum (7 pieces per day)
Trial: 7653318
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg nicotine gum (15 pieces per day)
Trial: 7653318
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg nicotine gum (30 pieces per day)
Trial: 344341
Drug: Immunofluorescence‐nDNA antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunofluorescence‐nDNA antibody test system